Pasithea Therapeutics Corp. (KTTA) Stock Price & Analysis
Pasithea Therapeutics Corp. (KTTA) rose 0.76% to USD 0.58 as of June 10, 2026 at 01:04 UTC, according to Nexqual real-time market data.
KTTA last closed at USD 0.58; the session ranged USD 0.54–0.58 on volume of 300,113 shares. Market capitalization is $19.38M, with a 52-week range of USD 0.28–2.06 (NCM). Source: Nexqual, June 10, 2026 at 01:04 UTC.
Key Statistics (as of June 10, 2026 at 01:04 UTC)
| Price | USD 0.58 |
|---|---|
| Change | ▲ 0.76% (up) |
| Previous Close | USD 0.58 |
| Open | USD 0.57 |
| Day Range | USD 0.54 – 0.58 |
| 52-Week Range | USD 0.28 – 2.06 |
| Volume | 300,113 shares |
| Market Cap | $19.38M |
| Exchange | NCM |
Technical Analysis (KTTA)
Nexqual's technical model rates KTTA "SELL" based on 2 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 01:04 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 29.89 (oversold) |
| vs SMA50 | Below (USD 0.73) |
| MACD | -0.04 (negative) |
Analyst Ratings (KTTA)
Wall Street analysts rate KTTA "None" based on 1 analysts, with a mean price target of USD 3 (range USD 3–3), per Nexqual as of June 10, 2026 at 01:04 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 3 |
| High Target | USD 3 |
| Low Target | USD 3 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (KTTA)
| EPS Estimate | USD -0.16 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.12 vs est -0.45 ▲ beat |
| 2025-12-31 | USD -0.89 vs est -0.18 ▼ miss |
Source: Nexqual, June 10, 2026 at 01:04 UTC.
Financials & Fundamentals (KTTA)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -58.22% |
| Current Ratio | 35.4 |
| Total Cash | $50.40M |
| Total Debt | $0 |
| Free Cash Flow | $-11.84M |
Source: Nexqual, June 10, 2026 at 01:04 UTC.
Financial Health Score (KTTA)
Nexqual rates Pasithea Therapeutics Corp.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 01:04 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $50M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$17M |
| Efficiency | Critical — ROE -58%, ROA -31.5% |
Ownership (KTTA)
| Insider Ownership | +1.11% |
|---|---|
| Institutional Ownership | +60.04% |
| Shares Outstanding | 33.41M |
| Float | 18.68M |
| Short % of Float | +0.83% |
Source: Nexqual, June 10, 2026 at 01:04 UTC.
Leadership (KTTA)
Pasithea Therapeutics Corp. is led by Tiago Reis Marques (age 47), CEO & Director, per Nexqual as of June 10, 2026 at 01:04 UTC.
| CEO & Director | Tiago Reis Marques (age 47) |
|---|---|
| Co-Founder & Executive Chairman | Lawrence Steinman BA (age 77) |
| Chief Financial Officer | Daniel H. Schneiderman (age 47) |
Major Backers & Investors (KTTA)
Notable institutional backers of Pasithea Therapeutics Corp. include Adage Capital Partners GP L.L.C., Squadron Capital Management LLC, Vivo Capital, LLC, according to Nexqual as of June 10, 2026 at 01:04 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Adage Capital Partners GP L.L.C. | 8.42% |
| Squadron Capital Management LLC | 8.42% |
| Vivo Capital, LLC | 8.42% |
| Janus Henderson Group PLC | 8.42% |
| Ameriprise Financial, Inc. | 5.42% |
| Cable Car Capital, LP | 4.84% |
| Stonepine Capital Management, LLC | 3.33% |
| AdvisorShares Trust-AdvisorShares Psychedelics ETF | 3.21% |
Source: Nexqual, June 10, 2026 at 01:04 UTC.
From Pasithea Therapeutics Corp.'s Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- Our policy is to actively seek to obtain, where appropriate, the broadest intellectual property protection possible for our current product candidates and any future product candidates, proprietary information and proprietary technology through a combination contractual arrangements and patents, both in the United States and abroad.
- While we believe that our technology, development experience and scientific knowledge provide us with competitive advantages, we face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical, and biotechnology companies, academic institutions, governmental agencies and public and private research institutions.
Partnerships
- To date, we have created over 100 analogs of our 20 priority hits as provided via our past screening partnership with Evotec.
- The terms of the Alpha-5 Agreement were approved by (i) the disinterested members of the audit committee ("Audit Committee") of Board and (ii) the disinterested members the Board, under the Company's related party transaction policy.   In connection with the Alpha-5 Agreement, each of the employees of Alpha-5 entered into employment agreements with the Company.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BFRI | Biofrontera Inc. | USD 0.88 | ▼ 5.88% |
| ISPC | iSpecimen Inc. | USD 2.92 | ▼ 3.31% |
| ENSC | Ensysce Biosciences, Inc. | USD 0.25 | ▲ 0% |
| PTPI | Petros Pharmaceuticals, Inc. | USD 0.01 | ▲ 8.33% |
| SOPAQ | Society Pass Incorporated | USD 0.05 | ▼ 16.67% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 01:04 UTC. This page is informational and not investment advice.